anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: The surgeon will administer bupivacaine as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.

Bupivacaine Injection: Used as cranial block for craniotomy surgery
Eligibility criteria:
Inclusion Criteria:

≥18 years of age
Need for elective supratentorial craniotomy
Preoperative GCS > 13

Exclusion Criteria:

Preoperative GCS ≤ 13
Child (<18 years of age)
Inability to understand or use the visual analog scale (VAS)
Proven or suspected allergy to local anesthetics
Craniotomy incision extending beyond the field of the block
Patients chronically (more than 2 wk) treated with narcotic medications
Previous scalp incision
Bilateral craniotomies
Allergies to local anesthetics
GCS verbal score < 4 after extubation
Patients whose surgeries extend past 6 hours (will be placed on standard of care and removed from study)
Patients currently on ergot-type oxytoxic drugs, MAOIs, or certain antidepressants
Lactating Mothers
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: The surgeon will administer Exparel (liposomal bupivacine) as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). 20 mL of Exparel will be diluted with saline to constitute 60 mL total. The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.

Liposomal bupivacaine: Used as cranial block for craniotomy surgery
Eligibility criteria:
Inclusion Criteria:

≥18 years of age
Need for elective supratentorial craniotomy
Preoperative GCS > 13

Exclusion Criteria:

Preoperative GCS ≤ 13
Child (<18 years of age)
Inability to understand or use the visual analog scale (VAS)
Proven or suspected allergy to local anesthetics
Craniotomy incision extending beyond the field of the block
Patients chronically (more than 2 wk) treated with narcotic medications
Previous scalp incision
Bilateral craniotomies
Allergies to local anesthetics
GCS verbal score < 4 after extubation
Patients whose surgeries extend past 6 hours (will be placed on standard of care and removed from study)
Patients currently on ergot-type oxytoxic drugs, MAOIs, or certain antidepressants
Lactating Mothers
Intervention: Furosemide
Trial phase: Phase 3
ATC code: C03CA01 | C03CB01 | C03EB01 | G01AE10
SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 82
Group description: Furosemide 20 mg, oral, once daily for 5 days

Furosemide: Furosemide 20 mg pill taken daily for 5 days
Eligibility criteria:
Inclusion Criteria:

Postpartum women
No antenatal diagnosis of hypertensive disorder of pregnancy at the time of admission for delivery, defined as existing chronic hypertension diagnosis or documented blood pressure of ≥140 systolic OR ≥90 diastolic on at least 2 occasions at least 4 hours apart prior to delivery admission who do not go on to get magnesium for seizure prophylaxis by the time of delivery
At least 18 years of age
English or Spanish speakers
One or more high risk factors for development of de novo postpartum hypertension

Exclusion Criteria:

Non-English or Spanish speakers
Women with a contraindication to diuretic therapy
Women who have used diuretics in the two weeks prior to delivery
Intervention: SODIUM CHLORIDE
Trial phase: Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 154
Group description: Apply topically to the inguinal region for 2 minutes
Eligibility criteria:
Inclusion Criteria:

Subjects of any race
Subjects in good health
Minimum skin flora baseline requirements on inguinal region

Exclusion Criteria:

Any tattoos, scars, breaks in the skin, or any form of dermatitis, or other skin disorders (including acne) on the applicable test area
Topical antimicrobial exposure within 14 days prior to screening and treatment days
Use of systemic or topical antibiotics, steroid medications, or any other products known to affect the normal microbial flora of the skin within 14 days prior to screening and treatment days
Intervention: ISOPROPYL ALCOHOL
Trial phase: Phase 3
ATC code: D08AX05
SMILES: CC(C)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: 70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation

70% v/v Isopropyl Alcohol Surgical Solution: Patient preoperative skin preparation
Eligibility criteria:
Inclusion Criteria:

Be male or female and at least 18 years of age.
Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English.
Be planning to undergo clean (class I wound) or clean-contaminated (class II wounds) surgery.
Expect to be available for up to 30-days after the surgery.

Exclusion Criteria:

Active infection or fever including evidence of infection at or adjacent to the operative site.
Immunosuppressed.
Kidney/liver failure.
Immunosuppressive therapy (chemotherapy, steroids) within the previous 1 week.
Any history of allergy to chlorhexidine or isopropyl alcohol or any other component in ZuraGard including citric acid, sodium citrate, methylparaben, or propylparaben, and FD&C Yellow #6.
Intervention: Chloraprep
Trial phase: Phase 3
SMILES: CC(C)O.NC(=NCCCCCCN=C(N)N=C(N)Nc1ccc(Cl)cc1)N=C(N)Nc1ccc(Cl)cc1.O=C(O)C(O)C(O)C(O)C(O)CO.O=C(O)CC(O)C(O)C(O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 26
Group description: 2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation

2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol: Patient preoperative skin preparation
Eligibility criteria:
Inclusion Criteria:

Be male or female and at least 18 years of age.
Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English.
Be planning to undergo clean (class I wound) or clean-contaminated (class II wounds) surgery.
Expect to be available for up to 30-days after the surgery.

Exclusion Criteria:

Active infection or fever including evidence of infection at or adjacent to the operative site.
Immunosuppressed.
Kidney/liver failure.
Immunosuppressive therapy (chemotherapy, steroids) within the previous 1 week.
Any history of allergy to chlorhexidine or isopropyl alcohol or any other component in ZuraGard including citric acid, sodium citrate, methylparaben, or propylparaben, and FD&C Yellow #6.
Intervention: Colchicine
Trial phase: Phase 1 | Phase 2
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Hospitalized covid-19 patients treated with colchicine plus current care per institution treating physicians.

Colchicine: Colchicine dosing = 0.6 mg bid x 30 days Decrease dose to 0.3-0.6 mg daily or every other day in setting of gastrointestinal intolerance (nausea, diarrhea, emesis, abdominal discomfort) Decrease dose to 0.6 mg daily in the setting of weak or moderate CYP3A4 inhibitor Decrease dose to 0.3 mg daily in the setting of strong CYP3A4, P-glycoprotein inhibitors, or protease inhibitors Decrease dose to 0.3 mg daily in the setting of chronic kidney disease (CKD) stage ≥ 4 (CrCl ≤ 30 ml/min) or liver failure (aspartate aminotransferase /alanine aminotransferase > 3x normal).

Decrease dose to 0.6 mg every 14 days in patients with end stage renal disease (ESRD) or requiring dialysis Route of Administration: oral
Eligibility criteria:
Inclusion Criteria:

Men and Women ≥ 18 years of age
Covid-19 Positive
Hospitalized patients able to provide informed consent

Cardiac injury (as evidenced by any of the following)

Elevated troponin level
Elevated BNP level
New ischemic or arrhythmogenic ECG/telemetry changes
New decrease in Left Ventricular Ejection Fraction (LVEF) or new pericardial effusion on echocardiogram

Exclusion Criteria:

Pregnancy, breastfeeding mothers, and women of childbearing age who are unable to use adequate contraception, which includes:

Intrauterine devices (IUD), contraceptive implants, or tubal sterilization
Hormone method with a barrier method
Two barrier methods
If a partner's vasectomy is the chosen method of contraception, a hormone or barrier method must also be used in conjunction
History of severe hematologic or neuromuscular disorder
Co-administration of Cytochrome P450 3A4 (CYPA3A4) and P-glycoprotein transport inhibitor
Severe renal impairment with concomitant hepatic impairment
Concurrent use of colchicine and strong or P-glycoprotein inhibitor with renal or hepatic impairment
Intervention: Bosentan
Trial phase: Early Phase 1
ATC code: C02KX01 | G01AE10
SMILES: COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Upon arriving at the laboratory, participants will ingest a liquid mixture containing Bosentan (125 mg), a non-selective blocker of endothelin-1 receptors ETA and ETB.

Bosentan 125 mg: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Eligibility criteria:
Inclusion Criteria:

Self-identification of their race and the race of their biological parents as being only Black (i.e., African American) or only White (i.e., Caucasian American)
Born and raised in the United States

Exclusion Criteria:

Mixed races
Any chronic or ongoing disease
Prescribed pharmacological treatment
Smoking or tobacco use
Obesity (body mass index > 30 kg / m2)
Intervention: Bosentan
Trial phase: Early Phase 1
ATC code: C02KX01 | G01AE10
SMILES: COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Upon arriving at the laboratory, participants will ingest a liquid mixture containing a placebo.

Bosentan 125 mg: Bosentan blocks endothelin-1 receptors ETA and ETB, leading to a reduction in vasoconstrictor tone and a greater magnitude of vasodilator responses.
Eligibility criteria:
Inclusion Criteria:

Self-identification of their race and the race of their biological parents as being only Black (i.e., African American) or only White (i.e., Caucasian American)
Born and raised in the United States

Exclusion Criteria:

Mixed races
Any chronic or ongoing disease
Prescribed pharmacological treatment
Smoking or tobacco use
Obesity (body mass index > 30 kg / m2)
Intervention: Ruxolitinib
Trial phase: Phase 3
ATC code: D11AH09 | L01EJ01 | L01XE18
SMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 256
Group description: Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
Willing to comply with the study visits and requirements of the study protocol.

Exclusion Criteria:

Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Intervention: Ruxolitinib
Trial phase: Phase 3
ATC code: D11AH09 | L01EJ01 | L01XE18
SMILES: N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 129
Group description: Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
Willing to comply with the study visits and requirements of the study protocol.

Exclusion Criteria:

Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
Treatment with systemic immunosuppressive medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Intervention: Mirtazapine
Trial phase: Phase 2
ATC code: N06AX11
SMILES: CN1CCN2c3ncccc3Cc3ccccc3C2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 13
Group description: The drug will be taken for a one week peroid.

Mirtazapine: 15 mg dose before bed-time
Eligibility criteria:
Inclusion Criteria:

Adults with SCI (>6months after spinal cord injury) at the T6 level/above
Non-injured adults

Exclusion Criteria:

Pregnant and lactating females
Heart failure, vascular disease, or stroke
Advanced chronic obstructive pulmonary disease (COPD), liver disease, and chronic kidney disease
BMI >38 kg/m2
Mechanical ventilation dependence
Intervention: Vancomycin
Trial phase: Phase 3
ATC code: A07AA09 | J01XA01 | S01AA28
SMILES: CN[C@H](CC(C)C)C(=O)N[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)O)c4cc(O)cc(O)c4-c4cc3ccc4O)[C@H](O)c3ccc(c(Cl)c3)Oc3cc2cc(c3O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O[C@H]2C[C@](C)(N)[C@H](O)[C@H](C)O2)Oc2ccc(cc2Cl)[C@H]1O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 2
Group description: Vancomycin dosed QID and a Ridinilazole placebo dosed BID, to maintain blind, for 40 doses over 10 days.

Vancomycin: Vancomycin 125mg dosed QID for 10 days.
Eligibility criteria:
Inclusion Criteria:

Is aged 12 to <18 years.
Has signs and symptoms of CDI including diarrhea such that in the Investigator's opinion CDI antimicrobial therapy is required, and the subject has tested positive for toxin A and/or B of C. difficile in the stool. Diarrhea is defined as ≥ 3 unformed bowel movements (UBMs) based on types 5, 6, 7 on the Bristol Stool Chart and diarrhea information is within 24 hours prior to randomization.

Exclusion Criteria:

Has had more than the equivalent of 48 hours of dosing of antimicrobial treatment active against the current episode of CDI prior to randomization.
Has received ridinilazole or an investigational vaccine against C. difficile any time in the past, anti-toxic antibodies including bezlotoxumab within the past 6 months, or any other investigational medicinal product for treatment of CDI or fecal microbiota replacement therapy within the past 3 months.
Has a clinically relevant positive stool test for pathogens other than C. difficile, within 48 hours of randomization.
Has life-threatening or fulminant CDI with evidence of hypotension, septic shock, peritoneal signs or absence of bowel sounds, toxic megacolon, or ileus.
Has had major GI surgery (e.g. significant bowel resection or pancreatectomy but not including appendectomy or cholecystectomy) within past 3 months or has the presence of a colostomy or ileostomy or has the likely requirement of an ostomy during the study.
Is receiving treatment that generally is associated with severe diarrhea, intractable vomiting, severe nausea, or inability to swallow that cannot be managed with antiemetics or antidiarrheals and that limits the ability to take oral medications. Cancer treatment that does not comprise ability to take study medication or cause severe diarrhea is allowed.
Intervention: (R)-2-((5-(1,2-Dithiolan-3-yl)pentanoyl)oxy)-N,N,N-trimethylethan-1-aminium chloride
Trial phase: Phase 2
SMILES: C[N+](C)(C)CCOC(=O)CCCCC1CCSS1.[Cl-]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 48
Group description: UNR844 5 mg/mL ophthalmic solution; one drop twice-a-day for three months
Eligibility criteria:
Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health
Intervention: (R)-2-((5-(1,2-Dithiolan-3-yl)pentanoyl)oxy)-N,N,N-trimethylethan-1-aminium chloride
Trial phase: Phase 2
SMILES: C[N+](C)(C)CCOC(=O)CCCCC1CCSS1.[Cl-]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 48
Group description: UNR844 13.3 mg/mL ophthalmic solution; one drop twice-a-day for three months
Eligibility criteria:
Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health
Intervention: (R)-2-((5-(1,2-Dithiolan-3-yl)pentanoyl)oxy)-N,N,N-trimethylethan-1-aminium chloride
Trial phase: Phase 2
SMILES: C[N+](C)(C)CCOC(=O)CCCCC1CCSS1.[Cl-]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 44
Group description: UNR844 23 mg/mL ophthalmic solution; one drop twice-a-day for three months
Eligibility criteria:
Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health
Intervention: (R)-2-((5-(1,2-Dithiolan-3-yl)pentanoyl)oxy)-N,N,N-trimethylethan-1-aminium chloride
Trial phase: Phase 2
SMILES: C[N+](C)(C)CCOC(=O)CCCCC1CCSS1.[Cl-]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 48
Group description: UNR844 30 mg/mL ophthalmic solution; one drop twice-a-day for three months
Eligibility criteria:
Inclusion Criteria:

Written informed consent must be obtained before any assessment is performed
Impaired near vision in each eye and when using both eyes, without any near correction
Need a certain level of near correction

Exclusion Criteria:

Impaired distance vision in either eye, with distance correction (if any)
Severe short- or long-sightedness
Any significant medical or clinical conditions affecting vision, the eyes or general health